Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients

Annals of Allergy, Asthma and Immunology

Volumn 101, Issue 3, 2008, Pages 287-294

  Patel, Piyush ^a,b   Patel, Deepen ^a,b  

^a Allied Research International Cetero Research   (Canada)

^b Allied Research International   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOCETIRIZINE; MONTELUKAST; PLACEBO; RAGWEED ANTIGEN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; ENVIRONMENTAL EXPOSURE; FATIGUE; FEMALE; FLUSHING; HAY FEVER; HEADACHE; HUMAN; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; SEDATION; SENSITIZATION; SIDE EFFECT; SNEEZING; TIME SERIES ANALYSIS;

EID: 51649087950     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60494-2     Document Type: Article

References (24)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108:S147-S334.
2. Task Force on Allergic Disorders. The Allergy Report. American Academy of Allergy Asthma and Immunology. http://www.aaaai.org/professionals.stm. Accessed September 17, 2007.
3. Bousquet J, Van Cauwenberge P, Ait KN, et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy. 2006;61:1086-1096.
4. Gelfand EW, Plaut M, Washington T, et al. Current trends in allergic reactions: a multidisciplinary approach to patient management. Interdisciplinary Med. 2003;5:1-12.
5. Van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis: European Academy of Allergology and Clinical Immunology. Allergy. 2000;55:116-134.
6. de Blic J, Wahn U, Billard E, Alt R, Pujazon MC. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol. 2005;16:267-275.
7. Leynadier F, Mees K, Arendt C, Pinelli ME. Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Otorhinolaryngol Belg. 2001;55:305-312.
8. Potter PC. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy. 2003;58:893-899.
9. Potter PC. Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial. Ann Allergy Asthma Immunol. 2005;95:175-180.
10. Bachert C, Bousquet J, Canonica GW, et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004;114:838-844.
11. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Revised Report, 2006. http://www.ginasthma.com/. Accessed September 16, 2007.
12. Chervinsky P, Philip G, Malice MP, et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol. 2004;92:367-373.
13. van Adelsberg J, Philip G, Pedinoff AJ, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy. 2003;58:1268-1276.
14. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol. 2002;88:592-600.
15. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32:1020-1028.
16. Day JH, Briscoe MP, Rafeiro E, Ratz JD. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract. 2004;58:109-118.
17. Stubner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit-the Vienna Challenge Chamber (VCC). Curr Med Res Opin. 2004;20:891-902.
18. Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol. 2005;60:24-31.
19. Day JH, Briscoe MP, Ratz JD. Efficacy of levocetirizine compared with montelukast in subjects with ragweed-induced seasonal allergic rhinitis in the environmental exposure unit. Allergy Asthma Proc. In Press.
20. Ciebiada M, Gorska-Ciebiada M, DuBuske LM, Gorski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97:664-671.
21. Lombardo G, Quattrocchi P, Lombardo GR, Galati P, Giannetto L, Barresi L. Concomitant levocetirizine and montelukast in the treatment of seasonal allergic rhinitis: influence on clinical symptoms. Ital J Allerg Clin Immunol. 2006;16:63-68.
22. Grainger J, Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and meta-analysis. Clin Otolaryngol. 2006;31:360-367.
23. Rodrigo GJ, Yanez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol. 2006;96:779-786.
24. Center for Drug Evaluation and Research. Allergic Rhinitis: Clinical Development Program for Drug Products. Draft Guidance 2000. Rockville, MD: Center for Drug Evaluation and Research, Food and Drug Administration, US Dept of Health and Human Services; 2000.